Literature DB >> 25269801

Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition.

Alexandra Nieters1, Anna Łuczyńska1, Susen Becker2, Nikolaus Becker3, Roel Vermeulen4, Kim Overvad5, Krasimira Aleksandrova6, Heiner Boeing6, Pagona Lagiou, Dimitrios Trichopoulos, Antonia Trichopoulou7, Vittorio Krogh8, Giovanna Masala9, Salvatore Panico10, Rosario Tumino11, Carlotta Sacerdote12, Bas Bueno-de-Mesquita13, Suzanne M Jeurnink13, Elisabete Weiderpass, Eva Ardanaz14, Maria-Dolores Chirlaque15, María-José Sánchez16, Soledad Sánchez17, Signe Borgquist18, Salma Butt19, Beatrice Melin20, Florentin Späth20, Sabina Rinaldi21, Paul Brennan22, Rachel S Kelly23, Elio Riboli21, Paolo Vineis24, Rudolf Kaaks3.   

Abstract

Previous epidemiological studies suggest an inverse association between allergies, marked by elevated immunoglobulin (Ig) E levels, and non-Hodgkin lymphoma (NHL) risk. The evidence, however, is inconsistent and prospective data are sparse. We examined the association between prediagnostic total (low: <20; intermediate: 20-100; high >100 kU/l) and specific IgE (negative: <0.35; positive ≥0.35 kU/I) concentrations against inhalant antigens and lymphoma risk in a study nested within the European Prospective Investigation into Cancer and Nutrition cohort. A total of 1021 incident cases and matched controls of NHL, multiple myeloma (MM) and Hodgkin lymphoma with a mean follow-up time of 7 years were investigated. Multivariate-adjusted odds ratios (ORs) with 95% confidence intervals (CI) were calculated by conditional logistic regression. Specific IgE was not associated with the risk of MM, B-cell NHL and B-cell NHL subtypes. In contrast, total IgE levels were inversely associated with the risk of MM [high level: OR = 0.40 (95% CI = 0.21-0.79)] and B-cell NHL [intermediate level: OR = 0.68 (95% CI = 0.53-0.88); high level: OR = 0.62 (95% CI = 0.44-0.86)], largely on the basis of a strong inverse association with chronic lymphocytic leukemia [CLL; intermediate level: OR = 0.49 (95% CI = 0.30-0.80); high level: OR = 0.13 (95% CI = 0.05-0.35)] risk. The inverse relationship for CLL remained significant for those diagnosed 5 years after baseline. The findings of this large prospective study demonstrated significantly lower prediagnostic total IgE levels among CLL and MM cases compared with matched controls. This corresponds to the clinical immunodeficiency state often observed in CLL patients prior to diagnosis. No support for an inverse association between prediagnostic levels of specific IgE and NHL risk was found.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25269801      PMCID: PMC4247516          DOI: 10.1093/carcin/bgu188

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  41 in total

Review 1.  Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.

Authors:  Nima Rezaei; Mona Hedayat; Asghar Aghamohammadi; Kim E Nichols
Journal:  J Allergy Clin Immunol       Date:  2011-04-22       Impact factor: 10.793

Review 2.  Immune defects in patients with chronic lymphocytic leukemia.

Authors:  Farhad Ravandi; Susan O'Brien
Journal:  Cancer Immunol Immunother       Date:  2005-07-16       Impact factor: 6.968

Review 3.  Altered immunity as a risk factor for non-Hodgkin lymphoma.

Authors:  Andrew E Grulich; Claire M Vajdic; Wendy Cozen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03-02       Impact factor: 4.254

4.  Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort.

Authors:  Alison Talbot-Smith; Lin Fritschi; Mark L Divitini; Dominic F J Mallon; Matthew W Knuiman
Journal:  Am J Epidemiol       Date:  2003-04-01       Impact factor: 4.897

5.  A prospective study of cancer incidence in a cohort examined for allergy.

Authors:  N E Eriksson; A Holmén; B Högstedt; Z Mikoczy; L Hagmar
Journal:  Allergy       Date:  1995-09       Impact factor: 13.146

6.  Association of alcohol consumption with total serum immunoglobulin E levels and allergic sensitization in an adult population-based survey.

Authors:  A González-Quintela; F Gude; O Boquete; J Rey; L M Meijide; F Suarez; M C Fernández-Merino; L F Pérez; C Vidal
Journal:  Clin Exp Allergy       Date:  2003-02       Impact factor: 5.018

7.  Occupational exposure to immunologically active agents and risk for lymphoma.

Authors:  Manolis Kogevinas; Jan-Paul Zock; Tomas Alvaro; Mercedes Garcia-Villanueva; Eva Domingo-Domenech; Susan Kennedy; Otoniel Martínez-Maza; Silvia de Sanjose
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-11       Impact factor: 4.254

8.  IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. A diagnostic approach.

Authors:  O Zetterström; S G Johansson
Journal:  Allergy       Date:  1981-11       Impact factor: 13.146

9.  Antitumor IgE adjuvanticity: key role of Fc epsilon RI.

Authors:  Elisa A Nigro; Anna T Brini; Elisa Soprana; Alessandro Ambrosi; David Dombrowicz; Antonio G Siccardi; Luca Vangelista
Journal:  J Immunol       Date:  2009-09-11       Impact factor: 5.422

10.  IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Authors:  Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

View more
  7 in total

1.  Antibodies as biomarkers for cancer risk: a systematic review.

Authors:  Maria J Monroy-Iglesias; Silvia Crescioli; Kerri Beckmann; Nga Le; Sophia N Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 2.  Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.

Authors:  Alex J McCraw; Jitesh Chauhan; Heather J Bax; Chara Stavraka; Gabriel Osborn; Melanie Grandits; Jacobo López-Abente; Debra H Josephs; James Spicer; Gerd K Wagner; Sophia N Karagiannis; Alicia Chenoweth; Silvia Crescioli
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.575

3.  Counting-based microfluidic paper-based devices capable of analyzing submicroliter sample volumes.

Authors:  Md Almostasim Mahmud; Eric J M Blondeel; Brendan D MacDonald
Journal:  Biomicrofluidics       Date:  2020-01-10       Impact factor: 2.800

4.  Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.

Authors:  Wahyu Wulaningsih; Lars Holmberg; Hans Garmo; Sophia N Karagiannis; Staffan Ahlstedt; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Tony Ng; Mieke Van Hemelrijck
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 8.110

5.  Allergic conditions are not associated with the risk of non-Hodgkin's lymphoma or Hodgkin's lymphoma: a systematic review and meta-analysis.

Authors:  Jia Yang; Hong'en Xu; Xiaodong Liang; Shiliang Lv; Baihua Lin; Yongshi Jia
Journal:  Onco Targets Ther       Date:  2017-04-18       Impact factor: 4.147

Review 6.  AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Authors:  E Jensen-Jarolim; H J Bax; R Bianchini; M Capron; C Corrigan; M Castells; D Dombrowicz; T R Daniels-Wells; J Fazekas; E Fiebiger; S Gatault; H J Gould; J Janda; D H Josephs; P Karagiannis; F Levi-Schaffer; A Meshcheryakova; D Mechtcheriakova; Y Mekori; F Mungenast; E A Nigro; M L Penichet; F Redegeld; L Saul; J Singer; J F Spicer; A G Siccardi; E Spillner; M C Turner; E Untersmayr; L Vangelista; S N Karagiannis
Journal:  Allergy       Date:  2017-01-23       Impact factor: 13.146

7.  Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.

Authors:  Panagiotis Georgiadis; Irene Liampa; Dennie G Hebels; Julian Krauskopf; Aristotelis Chatziioannou; Ioannis Valavanis; Theo M C M de Kok; Jos C S Kleinjans; Ingvar A Bergdahl; Beatrice Melin; Florentin Spaeth; Domenico Palli; R C H Vermeulen; J Vlaanderen; Marc Chadeau-Hyam; Paolo Vineis; Soterios A Kyrtopoulos
Journal:  BMC Genomics       Date:  2017-09-13       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.